If you have been reading about Maleimide chemistry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
==== Magnetic deflection ==== Thomson first investigated the magnetic deflection of cathode rays. Cathode rays were produced in the side tube on the left of the apparatus and passed through the anode into the main bell jar, where they were deflected by a magnet. Thomson detected their path by the fluorescence on a squared screen in the jar. He found that whatever the material of the anode and the gas in the jar, the deflection of the rays was the same, suggesting that the rays were of the same form whatever their origin.
=== Intraocular viscoelastic injection === It is used as an aid in ophthalmic surgery acting as aqueous and vitreous humor, e.g. in cataract extraction (intra- and extracapsular), intraocular lens implantation, corneal transplant, glaucoma filtration, and retina attachment surgery and in the treatment of dry eyes. In surgical procedures in the anterior segment of eyeball, instillation of sodium hyaluronate its viscoelasticity enables maintenance of a deep chamber during surgical manipulation since the solution does not flow out of the open anterior chamber, allowing for efficient manipulation with less trauma to the corneal endothelium and other surrounding tissues. Its viscoelasticity also helps to push back the vitreous face and prevent formation of a postoperative flat chamber. In posterior segment surgery, sodium hyaluronate serves as a surgical aid to gently separate, maneuver, and hold tissues. It creates a clear field of vision, facilitating intra-operative and post-operative inspection of the retina and photocoagulation.
=== Propagation === Seeds of A. chilensis germinate without cold stratification. In zones with the possibility of frost, it is recommended to sow in spring in a greenhouse. If they have grown enough, by autumn, the new plants can be planted into individual pots. The potted plants should stay in the greenhouse for the first winter. The following year, after the last expected frost in spring, the plants can be planted out into their final positions. In their first winter outdoors, some type of frost protection is required. For further propagation, vegetative propagation is possible: cuttings of wood with a length of 15 to 30 centimetres (5.9 to 11.8 in) can be planted into pots. These cuttings normally root, and can be planted out in the following spring.
Like the CNO-III, this branch is also only significant in massive stars. The reactions are started when one of the reactions in CNO-III results in fluorine-19 and a photon instead of nitrogen-15 and an alpha particle, and continues
Sources: en.wikipedia.org
Other studies have found higher rates of link rot in academic literature but typically suggest a half-life of four years or greater. A 2013 study in BMC Bioinformatics analyzed nearly 15,000 links in abstracts from Thomson Reuters's Web of Science citation index and found that the median lifespan of web pages was 9.3 years, and just 62% were archived. A 2021 study of external links in New York Times articles published between 1996 and 2019 found a half-life of about 15 years (with significant variance among content topics) but noted that 13% of functional links no longer lead to the original content—a phenomenon called content drift. A 2013 study found that 49% of links in U.S. Supreme Court opinions are dead. A 2023 study looking at United States COVID-19 dashboards found that 23% of the state dashboards available in February 2021 were no longer available at the previous URLs in April 2023. Pew Research found that, in 2023, 38% of pages from 2013 went missing. Also, in 2023, 54% of English Wikipedia articles had a dead link in the 'references' section and 23% of news articles linked to a dead URL.
=== Chemotherapy-induced neutropenia === Chemotherapy can cause myelosuppression and unacceptably low levels of white blood cells (leukopenia), making patients susceptible to infections and sepsis. G-CSF stimulates the production of granulocytes, a type of white blood cell. In oncology and hematology, a recombinant form of G-CSF is used with certain cancer patients to accelerate recovery and reduce mortality from neutropenia after chemotherapy, allowing higher-intensity treatment regimens. It is administered to oncology patients via subcutaneous or intravenous routes. A QSP model of neutrophil production and a PK/PD model of a cytotoxic chemotherapeutic drug (Zalypsis) have been developed to optimize the use of G-CSF in chemotherapy regimens with the aim to prevent mild-neutropenia. G-CSF was first trialled as a therapy for neutropenia induced by chemotherapy in 1988. The treatment was well tolerated and a dose-dependent rise in circulating neutrophils was noted. A study in mice has shown that G-CSF may decrease bone mineral density. G-CSF administration has been shown to attenuate the telomere loss associated with chemotherapy.
After wiping out a small German force about 50 km (31 mi) east of the Italian capital on 3 June, the 6th Division advanced north and captured the town of Paliano, then doubled back to the south-west and moved on Rome, which was reached on the morning of 6 June. A Squadron, Pretoria Regiment—that unit's squadron of Rhodesian tanks—entered the city as part of the division's vanguard. The German commander Albert Kesselring fought a stubborn delaying action, gradually withdrawing his armies north with three Allied columns in pursuit, the 6th Armoured Division leading the most westerly spearhead of the Eighth Army in the centre. The mountainous terrain and the effective use of anti-tank weapons by the retreating Germans made the Allies' superiority in armour less decisive and slowed the Allied advance north to the banks of the Arno between June and August 1944, during which time the Rhodesian tank squadrons took part in Allied victories at Castellana, Bagnoregio and Chiusi.
== Occurrence == The occurrence of unsaturated fats varies widely in nature. The saturated fatty acid components are almost exclusively stearic (C18) and palmitic acids (C16). Monounsaturated fats are almost exclusively oleic acid. Linolenic acid comprises most of the triunsaturated fatty acid component.
Like CMX-1152, the herbal mixture known as Protandim that supplanted it was marketed by Lifeline as an "anti-aging" supplement that increases the body's antioxidant defenses by upregulating superoxide dismutase, catalase, and glutathione peroxidase. According to the company, the product was initially sold through retail channels such as GNC; however, in 2009, after several consecutive years of multimillion-dollar losses, the company, which by then was doing business under the name LifeVantage, stopped marketing it through retailers and switched to multi-level marketing, selling it instead through a network of commissioned independent distributors. According to LifeVantage, the move from retail to multi-level marketing was prompted by the January 2008 hiring of David W. Brown, (formerly CEO and president of Metabolife) as the company's CEO and president. Beginning in 2005, Protandim was produced under a manufacturing agreement with The Chemins Company of Colorado Springs, Colorado. In July 2008, LifeVantage entered into a new manufacturing agreement with Cornerstone Research & Development to produce Protandim, and with Wasatch Product Development to produce a Protandim-based skin cream (TrueScience). In 2006, biochemist Joe M. McCord joined the LifeVantage board of directors as the company's director of science. McCord, who is listed by the U.S. Securities and Exchange Commission as a LifeVantage insider shareholder, served as a spokesperson for Protandim and was responsible for distributor training and product research.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.